FDAnews Drug Daily Bulletin

NEXMED TO APPEAL NASDAQ DELISTING DETERMINATION

July 5, 2006
A A

NexMed, Inc., a developer of innovative transdermal treatments based on the NexACT drug delivery technology, today announced that it has received a notice from Nasdaq indicating that it has not regained compliance in accordance with Marketplace Rule 4450(e)(4) as the market value of its common stock has remained below the minimum of $50,000,000 required for continued inclusion in the Nasdaq National Market.
Market Wire